Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Evaluation of the Clinical Utility of Circulating Biomarkers in Advanced Thyroid Carcinomas

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The study is aimed at all adult patients diagnosed with advanced thyroid carcinomas and well-differentiated thyroid carcinomas (DTC) iodine-refractory, well-differentiated iodine-refractory thyroid (RAI-R DTC) metastatic carcinomas that are candidates for systemic therapy. By simple blood sampling and analysis on peripheral blood of circulating DNA (ccf-DNA), circulating RNA (ccf-RNA), and counting and analysis of circulating tumor cells through the use of liquid biopsy, molecular profiling corresponding to those obtained by genomic sequencing on tumor tissue can be arrived at, depending on optimal therapeutic choices

Who May Be Eligible (Plain English)

Who May Qualify: - Signed written willing to sign a consent form, - Adult (≥18 years) male or female patients - Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review, - well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy, - Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue, - Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA). Who Should NOT Join This Trial: - Patients already receiving previous lines of systemic therapy, - Patients not eligible for systemic therapy. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Signed written informed consent, * Adult (≥18 years) male or female patients * Histologic diagnosis of advanced thyroid carcinoma confirmed at centralized review, * well-differentiated thyroid carcinomas, medullary thyroid carcinomas, anaplastic thyroid carcinomas, advanced, candidates for initiation of systemic medical therapy, * Availability of biomolecular profiling performed by multigenic NGS panel on tumor tissue, * Measurable disease by conventional imaging adopted in clinical practice (total body CT with mdc, CT-PET with FDG or F-DOPA). Exclusion Criteria: * Patients already receiving previous lines of systemic therapy, * Patients not eligible for systemic therapy.

Treatments Being Tested

DIAGNOSTIC_TEST

4 EDTA tubes of peripheral blood for Multigene analysis on ccf-DNA and ccf-RNA

For each patient enrolled in the present study, 4 EDTA tubes of peripheral blood will be collected to be used to obtain molecular profiling during scheduled laboratory controls as per normal clinical practice according to the following time schedule: * T0 = basal collection before initiation of systemic treatment; * T1 = sampling at 1 month after the start of systemic treatment; * T2 = sampling at 3 months (+/- 1 month) after the start of systemic treatment at the first instrumental re-evaluation of disease; * T3 = sampling at 6 months (+/- 1 month) from the start of systemic treatment at the time of instrumental disease reassessment; * T4 = sampling at the time of evidence of instrumental disease progression within 24 months of treatment initiation. The following analyses will be conducted on the samples thus collected: * multigenic analysis on ccf-DNA and ccf-RNA at baseline, i.e., before the initiation of systemic treatment; * isolation, counting and analysis of CTCs at baseline vi

Locations (1)

IRCCS Azienda Ospedaliero universitaria Bologna
Bologna, Italy